YAZ® in the treatment of premenstrual dysphoric disorder

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 53, Issue 9 SUPPL., 2008, Pages 729-741

  Rapkin, Andrea J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drospirenone; Oral contraceptives, combined; Premenstrual dysphoric disorder; YAZ

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; FLUOXETINE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PROGESTERONE DERIVATIVE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; YAZ; ANDROSTANE DERIVATIVE; ETHINYLESTRADIOL;

ANXIETY; ASTHENIA; BREAKTHROUGH BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; CONGENITAL HEART MALFORMATION; DEEP VEIN THROMBOSIS; DIAGNOSTIC TEST; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FOOD AND DRUG ADMINISTRATION; GABAERGIC SYSTEM; HEADACHE; HEART ARRHYTHMIA; HORMONE BLOOD LEVEL; HUMAN; HUMAN RELATION; HYPERKALEMIA; INSOMNIA; LIBIDO DISORDER; LOW DRUG DOSE; LUNG EMBOLISM; MASTALGIA; MOOD; MULTIPLE CYCLE TREATMENT; NAUSEA; OPTIMAL DRUG DOSE; PATHOGENESIS; POTASSIUM BLOOD LEVEL; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEDATION; SEROTONINERGIC SYSTEM; SIDE EFFECT; SOCIAL LIFE; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TREATMENT RESPONSE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VENOUS THROMBOEMBOLISM; WATER RETENTION; WEIGHT GAIN; XEROSTOMIA; ADOLESCENT; ADULT; ARTICLE; DRUG ADMINISTRATION; FEMALE; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; ETHINYL ESTRADIOL; FEMALE; HUMANS; PREMENSTRUAL SYNDROME; SEROTONIN UPTAKE INHIBITORS;

EID: 53649101810     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. YAZ® drospirenone/ethinyl estradiol prescribing information. Bayer HealthCare Pharmaceuticals Inc., Wayne, New Jersey, 2007
2. Ginsburg KA, Dinsay R: Premenstrual syndrome. In Practical Strategies in Obstetrics and Gynecology. Edited by SB Ransom. Philadelphia, WB Saunders, 2000, pp 684-694
3. Annual estimates of the population by sex and five-year age groups for the United States: April 1, 2002 to July 1, 2006. Available at: www.census.gov/popest/national/asrh/NC-EST2006/NC-EST2006-01.pdf. Accessed March 2008
4. Di Giulio G, Reissing ED: Premenstrual dysphoric disorder: Prevalence, diagnostic considerations, and controversies. J Psychosom Obstet Gynaecol 2006;27:201-210
5. Steiner M, Pearlstein T: Premenstrual dysphoria and the serotonin system: Pathophysiology and treatment. J Clin Psychiatry 2000;61:17-21
6. Halbreich U, Monacelli E: Some clues to the etiology of premenstrual syndrome/premenstrual dysphoric disorder. Prim Psychiatry 2004;11:33-40
7. Kendler KS, Karkowski LM, Corey LA, et al: Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry 1998;155:1234-1240
8. Halbreich U, Endicott J, Goldstein S, et al: Premenstrual changes and changes in gonadal hormones. Acta Psychiatr Scand 1986;74:576-586
9. Rubinow DR, Hoban MC, Grover GN, et al: Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am J Obstet Gynecol 1988;158:5-11
10. Backstrom T, Sanders D, Leask R, et al: Mood, sexuality, hormones, and the menstrual cycle: II. Hormone levels and their relationship to the premenstrual syndrome. Psychosom Med 1983;45:503-507
11. Facchinetti F, Genazzani AD, Martignoni E, et al: Neuroendocrine changes in luteal function in patients with premenstrual syndrome. J Clin Endocrinol Metab 1993;76:1123-1127
12. Rapkin AJ, Kuo J: Neurotransmitter physiology: The basics for understanding premenstrual syndrome. In The Premenstrual Syndromes: PMS and PMDD. Edited by PMS O'Brien, AJ Rapkin, PJ Schmidt. London, UK, Informa Healthcare, 2007, pp 69-81
13. Belelli D, Herd MB, Mitchell EA, et al: Neuroactive steroids and inhibitory neurotransmission: Mechanisms of action and physiological relevance. Neuroscience 2006;138:821-829
14. Backstrom T, Andersson A, Andree L, et al: Pathogenesis in menstrual cycle-linked CNS disorders. Ann N Y Acad Sci 2003;1007:42-53
15. Sundström Poromaa I, Smith S, Gulinello M: GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Women Ment Health 2003;6:23-41
16. Smith SS, Shen H, Gong QH, et al: Neurosteroid regulation of GABA(A) receptors: Focus on the alpha4 and delta subunits. Pharmacol Ther 2007;16:58-76
17. Rapkin AJ, Morgan M, Goldman L, et al: Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997;90:709-714
18. Monteleone P, Luisi S, Tonetti A, et al: Allopregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol 2000;142:269-273
19. Rapkin AJ, Edelmuth E, Chang LC, et al: Whole-blood serotonin in premenstrual syndrome. Obstet Gynecol 1987;70:533-537
20. Shah NR, Jones JB, Aperi J, et al: Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: A meta-analysis. Obstet Gynecol 2008;111:1175-1182
21. Magnay JL, Ismail KM, Chapman G, et al: Serotonin transporter, tryptophan hydroxylase, and monoamine oxidase A gene polymorphisms in premenstrual dysphoric disorder. Am J Obstet Gynecol 2006;195:1254-1259
22. Fink KB, Göthert M: 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 2007;59:360-417
23. Halbreich U: The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology (suppl 3) 2003;28:55-99
24. Rapkin AJ, Sorger SN, Winer SA: Drospirenone/ethinyl estradiol. Drugs Today (Barc) 2008;44:133-145
25. Halbreich U, Borenstein J, Pearlstein T, et al: The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology (suppl 3) 2003;28:1-23
26. Hylan TR, Sundell K, Judge R: The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: Experience from the United States, United Kingdom, and France. J Womens Health Gend Based Med 1999;8:1043-1052
27. Borenstein JE, Dean BB, Endicott J, et al: Health and economic impact of the premenstrual syndrome. J Reprod Med 2003;48:515-524
28. Borenstein J, Chiou CF, Dean B, et al: Estimating direct and indirect costs of premenstrual syndrome. J Occup Environ Med 2005;47:26-33
29. Borenstein JE, Dean BB, Leifke E, et al: Differences in symptom scores and health outcomes in premenstrual syndrome. J Womens Health (Larchmt) 2007;16:1139-1144
30. Yang M, Wallenstein G, Hagan M, et al: Burden of premenstrual dysphoric disorder on health-related quality of life. J Womens Health (Larchmt) 2008;17:113-121
31. Robinson RL, Swindle RW: Premenstrual symptom severity: Impact on social functioning and treatment-seeking behaviors. J Womens Health Gend Based Med 2000;9:757-768
32. Halbreich U, Backstrom T, Eriksson E, et al: Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007;23:123-130
33. American College of Obstetricians and Gynecologists: Practice bulletin: Premenstrual syndrome. Obstet Gynecol 2000;95:end of issue 4
34. American Psychiatric Association: Premenstrual dysphoric disorder. In Diagnostic and Statistical Manual of Mental Disorders. Fourth edition, text revision. Washington, American Psychiatric Association, 2000, pp 771-774
35. Freeman EW: The clinical presentation and course of premenstrual symptoms. In The Premenstrual Syndromes: PMS and PMDD. Edited by PMS O'Brien, AJ Rapkin, PJ Schmidt. London, Informa Healthcare, 2007, pp 55-61
36. Rapkin AJ, Winer SA: The pharmacologic management of premenstrual dysphoric disorder. Expert Opin Pharmacother 2008;9:429-445
37. Sarafem® fluoxetine hydrochloride tablets. Prescribing Information. Eli Lilly and Company, Indianapolis, Indiana, rev 2008. Available at: http://pi.lilly.com/us/sarafem.pdf. Accessed March 2008
38. Paxil CR® paroxetine hydrochloride controlled-release tablets. Prescribing information. GlaxoSmithKline, Research Triangle Park, North Carolina, 2007
39. Zoloft® sertraline hydrochloride tablets and oral concentrate. Prescribing information. Pfizer Inc., New York, New York, rev 2007
40. Rapkin AJ, Mikacich J: Clinical evaluation and management. In The Premenstrual Syndromes: PMS and PMDD. Edited by PMS O'Brien, AJ Rapkin, PJ Schmidt. London, Informa Healthcare, 2007, pp 149-159
41. Steiner M, Steinberg S, Stewart D, et al: Fluoxetine in the treatment of premenstrual dysphoria: Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995;332:1529-1534
42. Brown C, Ling FW: Premenstrual syndrome/premenstrual dysphoric disorder. In Clinical Gynecology. Edited by EJ Bieber, JS Sanfilippo, IR Horowitz. Philadelphia, Churchill Livingstone/Elsevier, 2006, pp 19-35
43. Ferguson JM: SSRI antidepressant medications: Adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001;3:22-27
44. Sundström-Poromaa I, Bixo M, Bjorn I, et al: Compliance to antidepressant drug therapy for treatment of premenstrual syndrome. J Psychosom Obstet Gynaecol 2000;21:205-211
45. FDA Public Health Advisory: Paroxetine. December 8, 2005. Available at: www.fda.gov/cder/drug/advisory/paroxetine200512.htm. Accessed March 2008
46. FDA Public Health Advisory: Treatment challenges of depression in pregnancy. July 19, 2006. Available at: www.fda.gov/cder/drug/advisory/ SSRI_PPHN200607.htm. Accessed March 2008
47. FDA revisions to product labeling. Available at: www.fda.gov/cder/drug/ antidepressants/antidepressants_label_change_2007.pdf. Accessed April 2008
48. Usman SB, Indusekhar R, O'Brien S: Hormonal management of premenstrual syndrome. Best Pract Res Clin Obstet Gynaecol 2008;22:251-260
49. Ross C, Coleman G, Stojanovska C: Prospectively reported symptom change across the menstrual cycle in users and non-users of oral contraceptives. J Psychosom Obstet Gynaecol 2003;24:15-29
50. Joffe H, Cohen LS, Harlow BL: Impact of oral contraceptive pill use on premenstrual mood: Predictors of improvement and deterioration. Am J Obstet Gynecol 2003;189:1523-1530
51. Krattenmacher R: Drospirenone: Pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38
52. Freeman EW, Kroll R, Rapkin A, et al: Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001;10:561-569
53. Mishell DR Jr: Rationale for decreasing the number of days of the hormone-free interval with use of low-dose oral contraceptive formulations. Contraception 2005;71:304-305
54. Sulak PJ, Scow RD, Preece C, et al: Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261-266
55. Yonkers KA, Brown C, Pearlstein TB, et al: Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492-501
56. Korner P, Yonkers KA, Niknian M: Reduction of symptoms related to negative interpersonal relationships, food, and water retention in women with premenstrual dysphoric disorder (PMDD) treated with an oral contraceptive containing drospirenone 3mg/ethinyl estradiol 20mcg in a 24/4 regimen (poster). Presented at the North American Society for Psychosocial Obstetrics and Gynecology Annual Meeting, Portland, Oregon, February 10, 2007
57. Pearlstein TB, Bachmann GA, Zacur HA, et al: Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72:414-421
58. Loughlin J, Seeger J, Eng PMJ, et al: Health outcomes in women taking ethinylestradiol/drospirenone and other oral contraceptives (abstr 154). Pharmacoepidemiol Drug Saf 2006;15:S72
59. Dinger JC, Heinemann LA, Kuhl-Habich D: The safety of a drospirenone-containing oral contraceptive: Final results from the European Active Surveillance Study on oral contraceptives based on 142,475 of observation. Contraception 2007;75:344-354
60. Seeger JD, Loughlin J, Eng PM, et al: Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007;110:587-593